2008 Trends to Watch: Pharmaceutical Technology

Publication Date	January 2008
Publisher	Datamonitor
Product Type	Report
Pages	13
ISBN Number	not applicable
Product Code	DAT09864

Price

£1,000.00
approximately: $1,868 | €1,268

PDF

PRINT £1,050 ($1,962 | €1,332)

Order above formats by FAX

Summary

Introduction

Technology markets are changing fast. This brief identifies and tracks the key forces shaping the prospects for your business. In this piece, Datamonitor's analyst specializing in pharmaceutical technology will outline the changes in the market, explain which trends will have the biggest impact, and highlight who will benefit from the fast-paced developments in pharmaceutical technology.

Scope

An overview of the challenges facing the life science industry in 2008
Datamonitor's take on the technology priorities of pharmaceutical and biotechnology companies
Strategies to help technology vendors penetrate the life science industry

Highlights

As the specter of generic competition grows, streamlining operations to reduce costs and time-to-market of a drug will be a top priority for pharmaceutical companies.

The life science industry must embrace technology solutions as it shifts away from the blockbuster drug business model.

Data management is a key issue affecting the life sciences. As drug regulatory agencies demand more clinical and post-market data, clinical IT solutions will become crucial to the industry.

Reasons to Purchase

Learn about the top trends in the life science industry in 2008
Identify strategies for expanding business opportunities in the life science industry
Tailor your go-to-market strategy to address critical issues facing pharmaceutical and biotechnology companies

Content

Datamonitor Viewcatalyst
Summary
Analysis
- The Industry Is Plagued By Generic Competition Due To Blockbuster Drugs Coming off Patent
- The Golden Age of Big Pharma And Blockbuster Drugs Is Over
- Mounting Drug Safety Concerns Puts Pressure On Regulatory Bodies, Especially The Fda
- Pharmaceutical Companies Accuse The Fda of Being Overly-Cautious
- Pharmaceutical Companies Are Restructuring Their Business Models To Adapt To The Changing Environment
- The Pharmaceutical Industry Turns To Biotechnology For The Next Blockbuster
Actions
- Impact On The Life Science Industry
- It Is Essential For The Life Science Industry To Streamline Operations
- The Pharmaceutical Industry Must Embrace It To Shift Away From The Blockbuster Drug Business Model
- New Regulations Will Require Companies To Have Better Data Management
- Recommendations For Technology Vendors
- Vendors Need To Demonstrate That It Solutions Will Optimize Business Processes
- It Vendors Must Prove Their Products Will Aid Global Market Development
- Customer Focus Is Essential To Penetrate The Market
Appendix
- Definitions
- Methodology
- Further Reading
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
List of Figures
- Figure 1: Drug Discovery & Development Process
- Figure 2: Number of Branded Drugs Going off Patent Between 2008-2012
- Figure 3: Number of New Molecular Entities (Nmes) And Biologics Approved By The Fda, 1980-2007
- Figure 4: Number of Layoffs Announced By Big Pharma In 2006-2007